Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The transaction is expected to close in the first quarter of 2022
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
A toll-free helpline to be set up to help doctors and patients
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
The product is expected to be available in a week’s time
Subscribe To Our Newsletter & Stay Updated
